Century Therapeutics (IPSC) Short term Debt (2021 - 2026)

Century Therapeutics (IPSC) has 5 years of Short term Debt data on file, last reported at $1.9 million in Q1 2026.

• Short term Debt for Q1 2026 came in at $1.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (changed N/A YoY), and the FY2025 annual result was $3.8 million, changed N/A from the prior year.
• Short term Debt retreated to $1.9 million in Q1 2026 per IPSC's latest filing, from $3.8 million in the prior quarter.
• Over five years, Short term Debt peaked at $10.3 million in Q1 2023 and troughed at $1.6 million in Q2 2022.
• A 4-year average of $5.2 million and a median of $4.0 million in 2022 frame the typical range for Short term Debt.
• On a YoY basis, Short term Debt climbed as much as 525.79% in 2022 and fell as far as 525.79% in 2022.
• A 4-year view of Short term Debt shows it stood at $6.5 million in 2022, then surged by 58.37% to $10.3 million in 2023, then tumbled by 63.51% to $3.8 million in 2025, then sank by 48.39% to $1.9 million in 2026.
• Business Quant data shows IPSC's Short term Debt at $1.9 million in Q1 2026, $3.8 million in Q4 2025, and $8.3 million in Q3 2025.